ANI Other Cashflows From Financing Activities from 2010 to 2025

ANIP Stock  USD 55.01  0.50  0.92%   
ANI Pharmaceuticals Other Cashflows From Financing Activities yearly trend continues to be relatively stable with very little volatility. Other Cashflows From Financing Activities is likely to grow to about -3.8 M this year. During the period from 2010 to 2025, ANI Pharmaceuticals Other Cashflows From Financing Activities destribution of quarterly values had r-value of  0.12 from its regression line and median of  809,000. View All Fundamentals
 
Other Cashflows From Financing Activities  
First Reported
2000-03-31
Previous Quarter
-9 M
Current Value
-57.3 M
Quarterly Volatility
46.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Other Cashflows From Financing Activities Growth Pattern

Below is the plot of the Other Cashflows From Financing Activities of ANI Pharmaceuticals over the last few years. It is ANI Pharmaceuticals' Other Cashflows From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Cashflows From Financing Activities10 Years Trend
Pretty Stable
   Other Cashflows From Financing Activities   
       Timeline  

ANI Other Cashflows From Financing Activities Regression Statistics

Arithmetic Mean34,549,261
Coefficient Of Variation261.58
Mean Deviation59,593,527
Median809,000
Standard Deviation90,374,647
Sample Variance8167.6T
Range356M
R-Value0.12
Mean Square Error8620.1T
R-Squared0.01
Significance0.65
Slope2,321,071
Total Sum of Squares122513.7T

ANI Other Cashflows From Financing Activities History

2025-3.8 M
2024-4 M
2023-3.5 M
20221.5 M
2021331.7 M
2020618 K
2019123.7 M

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Other Cashflows From Financing Activities, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Cashflows From Financing Activities-4 M-3.8 M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.